scholarly journals PS178. The Normalization of Brain 18F-FDG Hypometabolism following Electroconvulsive therapy in a 55-Year-Old Woman with Treatment-Resistant Late onset Depression: Case report

2016 ◽  
Vol 19 (Suppl_1) ◽  
pp. 64-64
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Late Onset ◽  
Treatment Resistant ◽  
18F Fdg

scholarly journals Catatonia Associated With Late Paraphrenia Successfully Treated With Lithium: A Case Report

2020 ◽  
Author(s):  
Hiroko Sugawara ◽  
Junpei Takamatsu ◽  
Mamoru Hashimoto ◽  
Manabu Ikeda
Keyword(s):  
Case Report ◽  
Mood Disorders ◽  
Electroconvulsive Therapy ◽  
Late Onset ◽  
Treatment Strategies ◽  
Psychotic Symptoms ◽  
Case Presentation ◽  
Limited Efficacy ◽  
Cumulative Evidence ◽  
The Brain

Abstract Background: Catatonia is a psychomotor syndrome that presents various symptoms ranging from stupor to agitation, with prominent disturbances of volition. Its pathogenesis is poorly understood. Benzodiazepines and electroconvulsive therapy (ECT) are safe and effective standard treatments for catatonia; however, alternative treatment strategies have not been established in cases where these treatments are either ineffective or unavailable. Here, we report a case of catatonia associated with late paraphrenia classified as very-late-onset schizophrenia-like psychosis, which was successfully treated with lithium. Case presentation: A 66-year-old single man with hearing impairment developed hallucination and delusions and presented with catatonic stupor after a fall. He initially responded to benzodiazepine therapy; however, his psychotic symptoms became clinically evident and benzodiazepine provided limited efficacy. Blonanserin was ineffective, and ECT was unavailable. His catatonic and psychotic symptoms were finally relieved by lithium monotherapy.Conclusions: Catatonic symptoms are common in patients with mood disorders, suggesting that lithium may be effective in these cases. Moreover, lithium may be effective for both catatonic and psychotic symptoms, as it normalizes imbalances of excitatory and inhibitory systems in the brain, which underlies major psychosis. Cumulative evidence from further cases is needed to validate our findings.

Brain-derived neurotrophic factor and electroconvulsive therapy in a schizoaffective patient with treatment-resistant paranoid-hallucinatory symptoms

2011 ◽  
Vol 26 (S2) ◽  
pp. 1148-1148
Author(s):  
G. Martinotti ◽  
V. Ricci ◽  
M. Di Nicola ◽  
C. Caltagirone ◽  
P. Bria ◽  
...  
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Neurotrophic Factor ◽  
Poor Response ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Treatment Resistant ◽  
Schizophrenic Patients ◽  
General Improvement ◽  
The Relationship

It has been proposed that deficits in the production and the utilization of brain-derived neurotrophic factor (BDNF) may contribute to the pathogenesis of schizophrenia. At the same time, electroconvulsive therapy (ECT) has been shown to induce a robust increase of BDNF protein in animal models. These findings suggest that one putative mechanism of action of ECT is the regulation of BDNF and/or related neurotrophins. In this case report a 54-year-old man with severe treatment-resistant schizophrenic symptoms was treated with ECT. In order to evaluate the effect of ECT on BDNF serum levels, we collected a blood sample before each ECT session. During the course of ECT treatment the paranoid and hallucinatory symptoms gradually improved while BDNF levels increased over time. In addition, there was a general improvement of its positive and negative schizophrenic symptoms and depressive state.In conclusion, this case report further validates the therapeutic efficacy of ECT in schizophrenic patients with inadequate or poor response to traditional treatments. Moreover, ECT therapeutic effect is associated with an increase in BDNF serum levels. Further studies are needed to characterize the relationship between BDNF and ECT in patients with schizophrenia symptoms.

scholarly journals Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington’s disease

2019 ◽  
Vol 12 (8) ◽  
pp. e230389 ◽  
Author(s):  
Hesitha Abeysundera ◽  
Allan Campbell ◽  
Shanthi Sarma
Keyword(s):  
Case Report ◽  
Huntington's Disease ◽  
Movement Disorder ◽  
Huntington’S Disease ◽  
Electroconvulsive Therapy ◽  
Movement Disorders ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Medical Practitioners ◽  
Resistant Depression

This paper describes a patient who presented with treatment-resistant depression with comorbid anxiety symptoms in the context of Huntington’s disease (HD) and developed worsening movement disorder symptoms after commencing electroconvulsive therapy (ECT) for depression. The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of worsening movement disorders when using ECT for depression in a patient with HD.

Treatment resistant late-onset depression with frontal cortical atrophy and neurocognitive impairment: A case report

2011 ◽  
Vol 26 (S2) ◽  
pp. 668-668
Author(s):  
E. Oral ◽  
M. Güleç ◽  
N. Aydin ◽  
E. Ozan ◽  
I. Kırpınar
Keyword(s):  
Case Report ◽  
Late Onset ◽  
Digit Span ◽  
Test Word ◽  
Frontal Lobes ◽  
Wisconsin Card Sorting Test ◽  
Neurocognitive Impairment ◽  
Cortical Atrophy ◽  
Treatment Resistant ◽  
Functional Changes

BackgroundLate-onset depression (after age 60) has more frequently been reported to be associated with brain abnormalities compared to early-onset depression. Consistent with the hypothesized role of frontolimbic circuits in the etiology of depression, the preponderance of cross-sectional studies of late-life clinical depression have revealed structural and functional changes in the frontal lobesCase reportNK was 70 years old female patient. She had a psychiatric history of five years with these symptoms. She had used several different antidepressants and benzodiazepines at adequate doses and some times low-dose atypical antipsychotics but she never had a full recovery. In this hospitalization, she was diagnosed as Major Depressive Disorder according to SCID-I. In MRI, we found generalized cortical atrophy especially in the frontal region. In neurocognitive tests, we realized that her minimental test score was 25. Wisconsin Card Sorting Test and Stroop test (main card reading time 54 seconds) showed disability in the executive functions such as cognitive flexibility, planning, decision making, overcoming of a strong habitual response or resisting temptation and in focused attention and working memory. The other cognitive domains evaluated with Rey Auditory learning test, Auditory trigram test, digit span test, trial making test, word association test were found to be normal. Conclusion: Treatment-resistant depression (TRD) is usually conceptualized as a failure to respond to several courses of adequate antidepressant treatment. Our findings can be suggested that cortical atrophy in especially frontal lobes can be consistent with a treatment resistance and neurocognitive impairment.

scholarly journals Young patient with treatment-resistant schizophrenia drastically improved by combination of clozapine and maintenance electroconvulsive therapy: a case report

2019 ◽  
Vol Volume 12 ◽  
pp. 185-188 ◽  
Author(s):  
Masashi Ito ◽  
Yasuto Kunii ◽  
Sho Horikoshi ◽  
Itaru Miura ◽  
Shuntaro Itagaki ◽  
...  
Keyword(s):  
Case Report ◽  
Young Patient ◽  
Electroconvulsive Therapy ◽  
Treatment Resistant

scholarly journals Repetitive transcranial magnetic stimulation induced hypomanic symptoms in a woman with a history of electroconvulsive therapy induced mania:  a case report

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 284 ◽  
Author(s):  
Noah S. Philip ◽  
S. Louisa Carpenter
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Transcranial Magnetic Stimulation ◽  
Electroconvulsive Therapy ◽  
Magnetic Stimulation ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Treatment Resistant ◽  
Major Depressive ◽  
Psychiatric Illnesses ◽  
History Of

Repetitive transcranial magnetic stimulation (rTMS) is a comparatively novel option for the treatment of major depressive disorder (MDD) and other psychiatric illnesses. Previous research has shown rTMS to be safe and without significant side effects compared to pharmacologic options. However, rare cases of rTMS-induced mania have been reported. This case report describes such an affective switch in a 52 year old female veteran with treatment-resistant MDD and a history of electroconvulsive therapy (ECT)-induced mania. Six treatments of rTMS were administered at 5 Hz for a total of 3000 pulses per day, when the patient began to display multiple hypomanic symptoms. These symptoms decreased after the termination of treatment and abated within a couple of days. In conclusion, caution should be used when administering rTMS to patients with a history of ECT-induced mania.

scholarly journals Saving the Fetus in Maternal Schizophrenia: The Role and Safety of Electroconvulsive Therapy (ECT) in Pregnancy.

2018 ◽  
Vol 1 (1) ◽  
pp. 48-52
Author(s):  
Othman Abdul Karim ◽  
Noraslawati R ◽  
Anisah J ◽  
Syaratul Emma H
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Electroconvulsive Therapy ◽  
First Trimester ◽  
Treatment Resistant ◽  
Pharmacological Interventions ◽  
Antipsychotic Medications ◽  
Long Duration ◽  
Clinical Dilemma ◽  
In Pregnancy

Introduction: Managing schizophrenia during pregnancy often presents a clinical dilemma. Although pharmacological interventions are mostly effective for these disorders during pregnancy, there are few drawbacks for this approach. The potential teratogenicity and long duration of interventions required to control the symptoms somehow limits its usage during pregnancy.Here we described a case report of treatment-resistant schizophrenia successfully treated with ECT without obvious complication to the mother and her baby.Conclusion: Electroconvulsive therapy is an ideal alternative treatment for a patient with schizophrenia during pregnancy. ECT also will eliminate the potential side effects of antipsychotic medications on the mother and teratogenicity effect to the fetus, especially during the first trimester.

scholarly journals Gamma-hydroxybutyric acid-induced organic delirium complicated by polydrug use successfully treated with electroconvulsive therapy: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Mads F. Kjærgaard ◽  
Poul Videbech ◽  
Jens J. Nørbæk ◽  
Bjørn H. Ebdrup
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Psychiatric Ward ◽  
High Dose ◽  
Line Treatment ◽  
Hydroxybutyric Acid ◽  
Treatment Resistant ◽  
First Line ◽  
Polydrug Use ◽  
First Line Treatment

Abstract Background Patients with gamma-hydroxybutyric acid withdrawal symptoms are at high risk of developing organic delirium, which can be fatal. The recommended first-line treatment is benzodiazepines, but treatment-resistant cases are frequent. Here we describe a case of successful bilateral electroconvulsive therapy in a patient with severe and highly agitated acute organic delirium induced by gamma-hydroxybutyric acid withdrawal and complicated by polydrug use resistant to first-line treatment. To our knowledge, this is the first report on the effect of electroconvulsive therapy on treatment-resistant delirium caused by gamma-hydroxybutyric acid withdrawal. Case presentation A 21-year-old Danish man diagnosed with untreated attention deficit hyperactivity disorder developed severely agitated acute organic delirium caused by gamma-hydroxybutyric acid withdrawal in a Danish psychiatric ward. The patient was subjected to physical restraints and transferred to the intensive care unit for treatment. During the next 10 days, the patient showed no clinical improvement despite first-line, high-dose benzodiazepines along with intense supportive treatment with propofol, phenobarbital, and antipsychotics. On day 11, bilateral frontotemporal electroconvulsive therapy treatment was initiated and full clinical recovery was obtained after four sessions. Discussion The full clinical remission after four electroconvulsive therapy sessions, strongly supports that electroconvulsive therapy may be an effective treatment when severe delirium induced by gamma-hydroxybutyric acid withdrawal is resistant to conventional first-line treatment with benzodiazepines. Moreover, this case illustrates that clinically effective seizures were achieved despite intensive concurrent exposure to anticonvulsive drugs. Therefore, this case report encourages consideration of electroconvulsive therapy in patients with gamma-hydroxybutyric acid delirium who are resistant to psychopharmacological treatment.

Sign in / Sign up

Export Citation Format

Share Document